Table 2.
The association between D-MMR EC and clinicopathological characteristics
| Clinicopathological characteristics in EC | Pooled % portion (95% CI) | No. of studies | I2 (95% CI, %) | p-value | Model |
|---|---|---|---|---|---|
| Overall D-MMR mutation | 24.477 (21.022–28.106) | 25 | 91.890 (89.250–93.880) | < .001 | Random effect |
| D-MMR mutation in type I | 25.810 (22.503–29.261) | 14 | 80.440 (68.080–88.020) | < .001 | Random effect |
| D-MMR mutation in type II | 13.736 (8.392–20.144) | 10 | 77.320 (58.360–87.650) | < .001 | Random effect |
| Stage I–II | 79.430 (71.500–86.357) | 6 | 68.640 (25.980–86.710) | .007 | Random effect |
| Stage III–IV | 20.168 (13.746–27.469) | 6 | 61.850 (7.020–84.350) | .022 | Random effect |
| Grade I–II | 65.718 (52.602–77.714) | 10 | 91.700 (86.860–94.760) | < .001 | Random effect |
| Grade III | 21.529 (15.930–27.718) | 10 | 94.050 (90.97–96.08) | < .001 | Random effect |
| Lymphovascular invasion | 32.105 (21.371–43.896) | 10 | 91.380 (86.270–94.590) | < .001 | Random effect |
| MI less than 50% | 51.807 (38.514–64.971) | 8 | 89.860 (82.410–94.150) | < .001 | Random effect |
| MI more than 50% | 42.346 (28.576–56.750) | 8 | 91.360 (85.380–94.890) | < .001 | Random effect |
D-MMR, mismatch repair deficiency; EC, endometrial carcinoma; CI, confidence interval; MI, myometrial invasion.